CytoDyn Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

(Loss) Income per Share (Tables)

(Loss) Income per Share (Tables)

6 Months Ended

Nov. 30, 2024

(Loss) Income per Share

Schedule of reconciliation of the numerators and denominators of basic and diluted net (loss) income per share


		Three months ended November 30,						Six months ended November 30,
(in thousands, except per share amounts)		2024			2023			2024			2023
Numerator:
Net (loss) income		$	(4,768)		$	(9,563)		$	14,459		$	(21,134)
Less: Accrued preferred stock dividends			(369)			(368)			(741)			(741)
Net (loss) income applicable to common stockholders		$	(5,137)		$	(9,931)		$	13,718		$	(21,875)
Denominator:
Basic weighted average common shares outstanding			1,221,405			958,988			1,177,988			941,191
Effect of dilutive securities:
Warrant exercises			—			—			26,205			—
Diluted weighted average common shares outstanding			1,221,405			958,988			1,204,193			941,191

Basic (loss) income per share		$	(0.00)		$	(0.01)		$	0.01		$	(0.02)
Diluted (loss) income per share		$	(0.00)		$	(0.01)		$	0.01		$	(0.02)

Schedule of securities excluded from computation of earnings per share


	Three and six months ended November 30,
(in thousands)	2024		2023
Stock options, warrants, and unvested restricted stock units	240,898		312,956
Convertible notes	12,000		12,000
Convertible preferred stock	38,533		35,558